For following the competition: what moved in each program, several studies read as one move.
- pacritinib
- S241656
- Anti-CG1/Anti-CD3 Bispecific T-cell Engager CBX-250
- + 1 more
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Leukemia, Myelomonocytic, Chronic to watchlistEvery Monday by email · turn it off any timePro · free during the beta